Takashi Shimada
Vermögen: 181 487 $ am 31.05.2026
Vermögen: 181 487 $ am 31.05.2026
Takashi Shimada is currently Chairman at KMT Hepatech, Inc. since 2017, Chairman at PhoenixBio USA Corp.
since 2018, and President & Representative Director at PhoenixBio Co., Ltd. since 2018.
Formerly, Mr. Shimada was Director & Administration Manager at Institute of Immunology Co., Ltd.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PHOENIXBIO CO., LTD. 1,68 % | 30.09.2025 | 68.300 ( 1,68 % ) | 181 487 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| PHOENIXBIO CO., LTD. | Präsident | 28.06.2018 |
PhoenixBio USA Corp.
PhoenixBio USA Corp. Miscellaneous Commercial ServicesCommercial Services Develops technologies for mass propagation of human cells into laboratory animals | Vorsitzender | 01.06.2018 |
KMT Hepatech, Inc.
KMT Hepatech, Inc. Miscellaneous Commercial ServicesCommercial Services Develops methods to support human liver cells in a mouse that allows support of infections | Vorsitzender | 01.12.2017 |
| Unternehmen | Position | Ende |
|---|---|---|
Institute of Immunology Co., Ltd.
Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Develops and produces diagnostic reagents and monoclonal antibodies | Verwaltungsdirektor | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
KMT Hepatech, Inc.
KMT Hepatech, Inc. Miscellaneous Commercial ServicesCommercial Services Develops methods to support human liver cells in a mouse that allows support of infections | Commercial Services |
Institute of Immunology Co., Ltd.
Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Develops and produces diagnostic reagents and monoclonal antibodies | Health Technology |
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Develops technologies for mass propagation of human cells into laboratory animals | Commercial Services |
PhoenixBio USA Corp.
PhoenixBio USA Corp. Miscellaneous Commercial ServicesCommercial Services Develops technologies for mass propagation of human cells into laboratory animals | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen